Hoth Therapeutics Inc (HOTH) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.79 (-12.42%), Market cap $0.01B, 52-week low–high $0.51 ~ $2.07.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company i
Financial statements, price targets, institutional (13F) holdings and related news for Hoth Therapeutics Inc are updated in real time on BlackAll Trade.
Hoth Therapeutics Inc trades at $0.79 (-12.42%). Real-time quotes and charts are available on BlackAll Trade.
Hoth Therapeutics Inc has a market cap of about $0.01B.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II